



Pediatric B-cell Non-Hodgkin Lymphoma: 21-year Experience with FAB-LMB Protocols in a Single Institute in Greece

Apostolos Pourtsidis¹, Marina Servitzoglou^{1*}, Margarita Baka¹, Despina Bouhoutsou¹, Maria Varvoutsi¹, Dimitrios Doganis¹, Katherine Strantzia-Michail² and Helen Kosmidis¹

¹Department of Oncology, Children's Hospital "P. & A. Kyriakou", Thivon and Levadias, Greece

²Histopathology Laboratory, Children's Hospital "P. & A. Kyriakou", Thivon and Levadias, Greece

***Corresponding author:** Dr. Marina Servitzoglou, Department of Oncology, Children's Hospital "P. & A. Kyriakou" Thivon and Levadias, Athens 11527, Greece, Tel: 00302107452219, Fax: 00302132009104, E-mail: mservitzoglou@gmail.com

Abstract

Aims and background: Our objective was to analyze the clinical and demographic characteristics of children with B-cell lymphoma treated in a single center over the last two decades.

Methods: Data was collected by a retrospective review of the charts of all 76 patients treated to our unit, from 1990 to 2010, with FAB LMB 89, 96 protocols and 2003 modifications.

Results: The median age was 8.03 years, with a male predominance 3.7:1. According to LMB staging criteria, 7 patients (9.2%) were classified as Group A, 53 (69.7%) as B and 16 (21.1%) as C all but 1 with bone marrow involvement and in 8 combined with CNS involvement. Most of our patients (46/76 - 60.5%) had abdominal tumours. Eight children of A and B Group (8/60, 13.3%) were upgraded to Group C due to poor treatment response. Regarding outcome, 11 patients died, 8 due to disease, 3 due to toxicity, 2 in induction and 1 post autograft. Relapse occurred in 10 children (13.2%), all with abdominal disease, one of them with concurrent mediastinal involvement. Most relapsed patients (7/10) were initially treated as Group B (7/53, 13.2%), 2 as C and 1 as Group A. The outcome of relapsed children was dismal, as 6/10 (60%) died.

Conclusions: In our results, the survival rate is generally excellent (65/76, 85.53 %) more than one year off treatment, which generally means cure in B-cell lymphomas. Children with unsatisfactory response to treatment and recurrent disease have a dismal prognosis.

Keywords

Non-Hodgkin lymphoma, B-cell lymphoma, FAB-LMB protocol

Introduction

B-cell Non-Hodgkin Lymphoma (BL), is the third most common childhood lymphoid malignancy among children younger than 15 years after acute lymphoblastic leukemia (ALL) and Hodgkin lymphoma [1,2]. The most common subtype of Non-Hodgkin

Lymphoma (NHL) is Burkitt lymphoma, which is characterized by a high growth fraction and a short doubling time, making necessary the administration of intensive treatment with short gaps between the courses. The adaptation of treatment intensity to recognized prognostic factors resulted in high cure rates, mainly with the use of FAB-LMB protocols [3-6].

The aim of our study was to analyze our experience of the treatment with FAB-LMB protocols and analyze the clinical and demographic characteristics of children with BL, treated in our Institute, the last two decades.

Patients and Methods

From January 1, 1990 to December 31, 2010, a total of 76 children with BL were treated in our Institute, all with FAB-LMB protocols, and more specifically with 89, 96 versions and 2003 modifications. Diagnosis was based on histomorphology and immunohistochemical analysis of lymph node or tumor mass biopsy, or on cytologic and immunophenotypic examination of malignant effusions. In more recent years, fluorescence *in situ* hybridization (FISH) for the specific for Burkitt lymphoma chromosomal translocation was also available. Disease staging was performed according to protocol staging system, dividing patients into 3 therapeutic groups (A - resected stage I and abdominal stage II); B - not eligible for A or C; and C - stages IV and L3 Acute Lymphoblastic Leukemia (ALL) with central nervous system (CNS) involvement or bone marrow involvement >25%). Response to treatment was assessed at 2 time points. Initially, at day 7 after COP (Cyclophosphamide / Vincristine / Prednisone): patients from Group A and B with tumour reduction less than 20% (poor response to COP) were switched to the more intensive group C regimen. The second evaluation was performed after the first consolidation course. Residual mass was recommended to be removed for histology or at least to be biopsied. Patients from Group B who had malignant cells in residual mass were also switched to group C.

The SPSS 17.0 software program was used for statistical

Citation: Pourtsidis A, Servitzoglou M, Baka M, Bouhoutsou D, Varvoutsi M, et al. (2015) Pediatric B-cell Non-Hodgkin Lymphoma: 21-year Experience with FAB-LMB Protocols in a Single Institute in Greece. Int J Blood Res Disord 2:014

Received: March 24, 2015: **Accepted:** May 06, 2015: **Published:** May 10, 2015

Copyright: © 2015 Pourtsidis A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Table 1: Clinical and demographic characteristics of the patients.

	Group A	Group B	Group C	Total
Localization				
Abdominal	4	31	11	46
ORL	1	8	2	11
Cervical	2	2		4
Bone		3		3
Other / combination		9	3	10
Results after COP				
> 25% response		48	15	63
< 25 % response		2	1	3
Results after CYM/CYVE				
CR		37	14	51
Residual mass	Viable tumour	7		
		6		
Primary treatment outcome				
CR	6	46	15	67
PR		0		
Resistant / progressive disease	1	3	1	5
Death due to disease		7	1	8
Death due to toxicity		2	1	3
Relapse				
Local	1	4		5
BM			2	2
Local + BM ± CNS		2		0
BM + CNS				0
CNS		1		1
Survival rate				
2-year OS	100%	83.1%	86.7%	
2-year EFS	85.7%	81.1%	81.3%	

calculations. Statistical analysis of outcome was performed using Kaplan-Meier life tables, differences compared by the log-rank test.

Results

Among the 76 children, the median age was 8.03 (3.05-16.25) years, with a male predominance 3.7:1. Among those children, 74 had Burkitt lymphoma and the other Diffuse Large B-cell lymphoma. In Table 1, there is a description of the patients according to staging, initial localization, and treatment outcome and survival rates. According to LMB staging criteria, 7 patients (9.2%) were classified as Group A, 53 (69.7%) as Group B and 16 (21.1%) as Group C, 15 with bone marrow involvement. Nine of the children had CNS disease, 8 in combination with marrow disease. Most of our patients (46/76 - 60.5%) had tumor mass in abdomen, 11 in head and neck (ENT) region, 3 in bones, 4 had cervical disease and 1 mediastinal disease. Eleven patients had more than one involved sites, in detail 2 had abdominal and mediastinal disease, 2 abdominal and ENT disease, 2 had abdominal and cervical involvement, 2 ENT and cervical tumours, 1 had axillary and inguinal disease, 1 ENT and mediastinal and 1 had abdominal and testicular involvement.

At the end of primary therapy, complete remission was achieved in 64 patients, while 5 had progressive or resistant disease. Of the remaining 7, 4 died early during treatment and 3 were in partial remission. In the entire cohort, 11 children died, 3 due to toxicity - 1 due to cerebral haemorrhage post COPADM #2 (Cyclophosphamide / Vincristine / Prednisone / Adriamycin / Methotrexate), and 2 due to septic shock, the first following COPADM #1 and the second at the basis of chronic graft versus host disease (GVHD), post stem cell transplantation (SCT) - and 8 due to disease. Among the latter, 1 has never started treatment due to severe presentation with respiratory failure and 1 has only undergone 1 cycle of treatment with steroids and monoclonal antibody anti-CD20, due to pre-existing renal failure.

Eight of the 60 children of A and B Group (13.3%) were upgraded to Group C, 1 due to poor response to chemotherapy prophase with COP and the remaining 7 because of viable tumour at the 2nd timepoint of remission assessment. Half of these children (4/8) died from disease.

Relapse occurred in 10 children (13.2%), all with abdominal disease, including one with concurrent thoracic involvement. The median time to relapse was 95 days (38-1170). Most relapsed patients (7/10) were initially treated as Group B (7/53, 13.2%), 2 as C and 1 as Group A. The outcome of relapsed children was dismal as 6/10 (60%) died, whilst the others entered complete remission.

Five children underwent SCT, 4 due to relapse and 1 due to primary treatment failure. Only 1 of these children survived, 1 died from transplant toxicity and the other 3 died from disease progression following successful engraftment.

Monoclonal antibody anti-CD-20 was administered in 3 patients, in 2 as salvage treatment, post disease progression during treatment and in the second, as initial treatment with steroids. Only 1 of them has entered remission.

Treatment outcome according to initial therapeutic group is described in Table 1. The OS for the entire cohort of 76 patients was 85.53% (65/76) and the EFS 83.78%, at 2 years, with a median follow-up time of 9.5 years (2-12). The survival analysis was performed based on intention to treat, as 1 patient died prior to commencing chemotherapy. According to the therapeutic group, the OS and the EFS was 100% and 85.7% for A, 83.1% and 81.1% for B, and for group C, 86.7% and 81.3%, respectively.

Grade 3 and 4 hematological toxicity with profound neutropenia and thrombocytopenia was noted in all patients following COPADM and CYVE (Cytarabine/Etoposide). At least one episode of neutropenic fever was noted in all 69 patients of group B and C, 60 of them had more than one episodes. Overall, we had 34 episodes of sepsis in 26 children. Twenty-five developed sepsis on the grounds of neutropenic fever following a course of chemotherapy and 1 before initiation of treatment. Other kind of infections were pneumonia in 8 cases, 1 of them fatal with ARDS picture, central venous catheter exit site infection in 5 cases, VZV infection in 2 cases, HSV in 2 patients, CMV in 1 child, H1N1 in 1 child, urine tract infection in 1 child, acute otitis media in 2 children, periodontal abscess in 1 child and genital infection in 1 child. Five children had more than 1 septic episode and 1 died from septic shock post COPADM #1, the cause unspecified. Twenty-one episodes were attributed to Gram negative bacteria (E.coli 5, Klebsiella 8, Pseudomonas 2, Enterobacter 2, Citrobacter 1, Acinetobacter 1, Achromobacter 1 and Proteus 1), 9 to Gram positive (Streptococcus 5, Staphylococcus coagulase negative 3, Staphylococcus coagulase positive 1), 1 to Candida, 2 to a combination of Gram positive and Gram negative (Streptococcus with Klebsiella in the 1st child and with Acinetobacter in the 2nd) and in 1 case, the only fatal, the cause was unspecified.

Mucositis was the second most frequent toxicity. It varied from grade II to IV and was noted following COPADM, mainly attributed to the combination of high-dose Methotrexate and Adriamycin. The development of mucositis did not correlate necessarily with delayed Methotrexate clearance. Oral mucositis was reported in 57 children post COPADM, in 14 of them post CYVE or 1st maintenance also.

In our population, 10 (13.7%) patients developed some form of impaired renal function or tumor lysis syndrome (TLS), which resolved in all cases. TLS was defined as an abnormally 25% increase in serum uric acid, potassium, and phosphorus levels over baseline and a 25% decrease from baseline in serum calcium levels. None of the children died because of TLS. Only 4 of those children (40% of TLS and 5.48% of the entire cohort) required haemodialysis. All of them had elevated LDH, bulk abdominal (one with concurrent ENT) disease and bone marrow involvement.

Discussion

The cure rates for B-cell mature lymphoma have substantially improved over the last decades, with the introduction of modern protocols (Table 2). Our OS and EFS were comparable to those reported in other countries, using FAB-LMB, BFM or CCG protocols [2,4,7-20]. This is the largest series of children with B-cell lymphoma, treated in our country, with very good results. As reported in other

Table 2: Treatment results of childhood B-cell NHL in different working groups.

Study	Country	No patients	Time period	Protocol	EFS	OS
Wessels et al. [7]	S. Africa	63	1983-2002	COMP, LMB-89,96	25-87%	
Reiter et al. [2]	Germany	111	1986-1990	BFM-86		81%
Burkhardt et al. [8]	International	1004	1986-2002	BFM-86, 90, 95	87%	
Patte et al. [4]	France	420	1989-1996	LMB-89	92%	
Müller et al. [9]	Hungary	108	1990-2004	BFM-90, 95	81%	83%
Cairo et al. [10]	USA	46	1991-1995	Orange, CCG-5911	80%	
Kavan et al. [11]	Czech Republic	82	1991-1997	BFM-90	74%	80%
Pillon et al. [12]	Italy	105	1992-1997	AIEOP-LNH 92	87.5%	
Chantada et al. [13]	Argentina	57	1994-1999	BFM-90	79%	81%
Marky et al. [14]	Nordic countries	121	1995-2000	NOPHONHL-95	91%	91%
Celkan et al. [15]	Turkey	48	1995-2007	BFM-95	76.6%	78.1%
Patte et al. [4]	France	397	1996-2001	LMB-96	93.3%	
Dokmanovic et al. [16]	Serbia	57	1997-2011	BFM-95	84.1%	93%
Eldar et al. [17]	Israel	88	2000-2005	LMB-96	88.6%	90.9%
Tsurusawa et al. [18]	Japan	321	2001-2012	B-NHL03	87.4%	92.7%
Sun et al. [19]	China	138	1998-2011	Modified BFM-90	85.8%	85.8%
Nelson et al. [20]	USA	90	1996-2001	CCG-5961		89%

countries, the children allocated to Group B represent the vast majority of patients [3,4]. Surprisingly, the cure rates for Group C are relatively higher than Group B; this could be attributed to the low number of patients in Group C.

Children from Group A have an excellent prognosis with minor treatment [5]. Children from Group B with unsatisfactory response at re-evaluation time points, and specifically following prophase and first consolidation course, seem to have dismal prognosis. In our cohort, the survival rate of children who were upgraded to higher regimen due to poor response to treatment was only 50% (4/8). Second-line treatment, targeted therapy and SCT might offer curable options for these children.

CNS involvement has been related to poor outcome in previous reports [21]. In our cohort, 9/76 (11.8%) children had CNS disease, percentage relatively higher to that reported by other Groups. On the contrary, this has not been a negative prognostic factor for our patients, as EFS and OS were 88.9% and 100%, respectively. Those patients with CNS and bone marrow involvement, classified as Group C, may have a very good prognosis, in view of the intensification of treatment and the improvement of supportive care, over the last two decades [22,23].

Only one of our patients who received a stem cell transplant, survived. The role of SCT in resistant and recurrent B-cell lymphoma has not been promising, apparently due to the aggressive nature of the disease [24].

Monoclonal antibody anti-CD20 has been administered in only 3 patients; in the first, as an upfront monotherapy (with steroids) and in the other 2, as part of second-line treatment for refractory disease. Only 1 of these patients reached remission. Even though the reports so far seem promising, we could not evaluate Rituximab in our population, due to the small number of recipients [23,25,26].

Myelosuppression was the main toxicity, as anticipated by such an intensive protocol. Despite the profound and long neutropenic periods in the children of our cohort, we had only one death due to sepsis. As a result, our EFS has not been particularly compromised. The increased supportive care measures with preemptive initiation of broad spectrum antibiotics and early diagnosis of infections are the main reason for their successful management. Children with neutropenic fever were treated with an antipseudomonal β -lactam, in combination with an aminoglycoside, until count recovery. A glycopeptide (mainly teicoplanin and rarely, vancomycin) was added in case of fever persisting more than 48 hours or if there was a suspicion of a Gram positive infection. Oral mucositis has been the second most frequent complication, related mainly to high-dose Methotrexate. Most episodes were noted following COPADM and less following CYVE and were predisposing to sepsis, as all children with sepsis had more severe than grade II mucositis. Mouth rinses

were used as a prophylaxis and treatment of mucositis. Acyclovir was used for severe mucositis and antifungals for severe oral thrush.

Elevated LDH and bulk disease are predisposing for TLS and increase supportive care measures are required. As it is reflected in our results, with the use of urate oxidase, which has been available in our country for more than a decade, the percentage of patients, even with advanced stage, who develop severe TLS, has fallen significantly [27].

In conclusion, the survival rates for children with B-cell Non-Hodgkin lymphoma in our Institution have been comparable to those reported in other developed countries. Children with poor response to treatment and recurrent disease have the worse prognosis. Larger sample, with multi-Institutional analysis should be performed in order to define prognostic factors and relate clinical and epidemiological variables with overall and disease-free survival.

References

1. Ries LAG, Melbert D, Krapcho M, Stinchcomb DG, Howlader N, et al. (2008) SEER Cancer Statistics Review, 1975-2005. National Cancer Institute; Bethesda, USA.
2. Reiter A (2007) Diagnosis and treatment of childhood non-hodgkin lymphoma. Hematology Am Soc Hematol Educ Program.
3. Miles RR, Arnold S, Cairo MS (2012) Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia. Br J Haematol 156: 730-743.
4. Patte C, Auperin A, Gerrard M, Michon J, Pinkerton R, et al. (2007) Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 109: 2773-2780.
5. Gerrard M, Cairo MS, Weston C, Auperin A, Pinkerton R, et al. (2008) Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 141: 840-847.
6. Patte C, Auperin A, Michon J, Behrendt H, Leverger G, et al. (2001) The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97: 3370-3379.
7. Wessels G, Bernard Hesseling P (2005) Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa. Transfus Apher Sci 32: 27-31.
8. Burkhardt B, Oschlies I, Klapper W, Zimmermann M, Woessmann W, et al. (2011) Non-Hodgkin's lymphoma in adolescents: experiences in 378 adolescent NHL patients treated according to pediatric NHL-BFM protocols. Leukemia 25: 153-160.
9. Muller J, Csoka M, Jakab Z, Pomyi A, Erlaky H, et al. (2008) Treatment of pediatric non-Hodgkin lymphoma in Hungary: 15 years experience with NHL-BFM 90 and 95 protocols. Pediatr Blood Cancer 50: 633-635.
10. Cairo MS, Sposto R, Perkins SL, Meadows AT, Hoover-Regan ML, et al. (2003) Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol 120: 660-670.

11. Kavan P, Kabickova E, Gajdos P, Koutecky J, Kodel R, McClain KL. (1999) Treatment of pediatric B-cell non-Hodgkin's lymphoma at the Motol Hospital in Prague, Czech Republic: results based on the NHL BFM 90 protocols. *Pediatr Hematol Oncol* 16: 201-212.

12. Pillon M, Di Tullio MT, Garaventa A, Cesaro S, Putti MC, et al. (2004) Long-term results of the first Italian Association of Pediatric Hematology and Oncology protocol for the treatment of pediatric B-cell non-Hodgkin lymphoma (AIEOP LNH92). *Cancer* 101: 385-394.

13. Chantada G, Casak S, Alderete D, Zubizarreta P, Gallo G, et al. (2003) Treatment of B-cell malignancies in children with a modified BFM-NHL 90 protocol in Argentina. *Med Pediatr Oncol* 41: 488-490.

14. Marky I, Bjork O, Foreister E, Jónsson OG, Perkkio M, et al. (2004) Intensive chemotherapy without radiotherapy gives more than 85% EFS for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology-oncology. *J Pediatr Hematol Oncol* 26: 555-560.

15. Celkan TT, Barış S, Ozdemir N, Ozkan A, Apak H, et al. (2010) Treatment of pediatric Burkitt lymphoma in Turkey. *J Pediatr Hematol Oncol* 32: 279-284.

16. Dokmanovic L, Krstovski N, Vukanic D, Brasanac D, Rodic P, et al (2012). Pediatric non-Hodgkin lymphoma: a retrospective 14-year experience with Berlin-Frankfurt-Munster (BFM) protocol from a tertiary care hospital in Serbia. *Pediatr Hematol Oncol* 29: 109-118.

17. Eldar AH, Futerman B, Abrahami G, Attias D, Barak AB, et al. (2009) Burkitt lymphoma in children: the Israeli experience. *J Pediatr Hematol Oncol* 31: 428-436.

18. Tsurusawa M, Mori T, Kikuchi A, Mitsui T, Sunami S, et al. (2014) Improved treatment results of children with B-cell non-Hodgkin lymphoma: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study. *Pediatr Blood Cancer*; 61: 1215-1221.

19. Sun XF, Zhen ZJ, Xia Y, Lin SX, Zhu J, et al. (2013) Outcomes of children and adolescents with Burkitt lymphoma and diffuse large B-cell lymphoma treated with a modified NHL-BFM-90 protocol. *Zhonghua Xue Ye Xue Za Zhi* 34: 1032-1037.

20. Nelson M, Perkins SL, Dave BJ, Coccia PF, Bridge JA, et al. (2010) An increased frequency of 13q deletions detected by fluorescence in situ hybridization and its impact on survival in children and adolescents with Burkitt lymphoma: results from the Children's Oncology Group study CCG-5961. *Br J Haematol* 148: 600-610.

21. Salzburg J, Burkhardt B, Zimmermann M, Wachowski O, Woessmann W, et al. (2007) Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. *J Clin Oncol* 25: 3915-3922.

22. Cairo MS, Gerrard M, Sposto R, Auperin A, Pinkerton CR, et al. (2007) Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. *Blood* 109: 2736-2743.

23. Sandlund JT, Murphy SB, Santana VM, Behm F, Jones D, et al. (2000) CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma. *J Clin Oncol* 18: 3018-3024.

24. Gross TG, Hale GA, He W, Camitta BM, Sanders JE, et al. (2010) Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. *Biol Blood Marrow Transplant* 16: 223-230.

25. Anoop P, Sankpal S, Stiller C, Tewari S, Lancaster DL, et al. (2012) Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. *Leuk Lymphoma* 53: 1882-1888.

26. Meinhardt A, Burkhardt B, Zimmermann M, Borkhardt A, Kontny U, et al. (2010) Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia. *J Clin Oncol* 28: 3115-3121.

27. Wössmann W, Schrappe M, Meyer U, Zimmermann M, Reiter A (2003) Incidence of tumor lysis syndrome in children with advanced stage Burkitt's lymphoma/leukemia before and after introduction of prophylactic use of urate oxidase. *Ann Hematol* 82: 160-165.